Tag: Biologics
GenSight Biologics: Laurence Rodriguez (ex-Sanofi) appointed CEO
(AOF) – GenSight Biologics announced the appointment of Laurence Rodriguez as Chief Executive Officer. The biotech specialist in gene therapies for retinal neurodegenerative diseases and central nervous system disorders specifies…
GenSight Biologics: a cash horizon extended until mid-December 2023
By Alexandra Saintpierre Published on 11/15/2023 at 6:14 p.m. Photo credit © Banque de France (Boursier.com) — The…
GenSight Biologics: the success of Lumevoq extends its horizon to mid-December 2023 – 11/15/2023 at 6:19 p.m.
(AOF) – GenSight Biologics announces that an independent laboratory confirms the viral titer of the second batch of Drug Substance (DS) for Lumevoq produced according to Good Manufacturing Practice (GMP)…
GenSight Biologics: the success of Lumevoq extends its horizon to mid-December 2023
(AOF) – GenSight Biologics announces that an independent laboratory confirms the viral titer of the second batch of Drug Substance (DS) for Lumevoq produced according to Good Manufacturing Practice (GMP)…
GenSight Biologics up sharply after production of 1st batch of GMP-compliant Lumevoq – 09/18/2023 at 11:06
(AOF) – GenSight Biologics (+60.78% to 0.66 euros) sees its stock skyrocket in high volumes after announcing that its production partner in the United States has successfully produced a batch…
Gensight biologics: The stock soars after an update on production
Read also (CercleFinance.com) – GenSight Biologics soars on the Paris Stock Exchange on Monday morning after announcing that it had successfully produced a batch of its gene therapy intended for…
GenSight Biologics: 1 million euros in cash, visibility until December – 09/15/2023 at 6:20 p.m.
(AOF) – GenSight Biologics sees its cash flow horizon extended until October 2023 thanks to the 1st tranche of financing of 10 million euros in August, and until December 2023…
GenSight Biologics: 1 million euros in cash, visibility until December
(AOF) – GenSight Biologics sees its cash flow horizon extended until October 2023 thanks to the 1st tranche of financing of 10 million euros in August, and until December 2023…
Gensight biologics: After its surprise U-turn for its flagship product, biotech GenSight collapses on the stock market
(BFM Bourse) – The company has chosen to abandon the process to obtain marketing authorization for Lumevoq from the European Medicines Agency. GenSight plans to produce new clinical data, which…
Gensight Biologics collapses after Lumevoq clearance request withdrawn – 04/21/2023 at 14:46
Lumevoq is a gene therapy treatment for Leber hereditary optic neuropathy (LHON). (illustration photo / Photo credits: Adobe Stock – ) (AOF) – GenSight Biologics loses 65.96% to 0.8340 euro…
GenSight Biologics: Lumevoq early access data confirms clinical trials – 03/15/2023 at 09:57
(AOF) – GenSight Biologics announces that the efficacy and safety data of patients with Leber Hereditary Optic Neuropathy (LHON) and carriers of the ND4 mutation treated with lenadogene nolparvovec (or…
GenSight Biologics: presentation of data on LUMEVOQ – 03/15/2023 at 10:28
(CercleFinance.com) – GenSight Biologics announces today that the efficacy and safety data of patients with Leber Hereditary Optic Neuropathy and carriers of the ND4 mutation treated with lenadogene nolparvovec (LUMEVOQÒ,…